Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 9 | 2024 | 847 | 0.890 |
Why?
|
Child | 92 | 2024 | 30136 | 0.870 |
Why?
|
Child, Preschool | 59 | 2024 | 16760 | 0.730 |
Why?
|
Adolescent | 73 | 2024 | 32276 | 0.710 |
Why?
|
Maximum Tolerated Dose | 15 | 2024 | 1314 | 0.650 |
Why?
|
Singing | 2 | 2016 | 6 | 0.600 |
Why?
|
Eosinophilic Esophagitis | 4 | 2021 | 73 | 0.590 |
Why?
|
Central Nervous System Neoplasms | 5 | 2024 | 547 | 0.550 |
Why?
|
Food Hypersensitivity | 4 | 2021 | 142 | 0.530 |
Why?
|
Autism Spectrum Disorder | 5 | 2021 | 374 | 0.530 |
Why?
|
Health Knowledge, Attitudes, Practice | 6 | 2021 | 1280 | 0.510 |
Why?
|
Peanut Hypersensitivity | 3 | 2022 | 71 | 0.510 |
Why?
|
Humans | 152 | 2024 | 270490 | 0.500 |
Why?
|
Neoplasm Recurrence, Local | 16 | 2024 | 10254 | 0.500 |
Why?
|
Male | 100 | 2024 | 127456 | 0.500 |
Why?
|
Female | 107 | 2024 | 147097 | 0.500 |
Why?
|
Proton Therapy | 6 | 2023 | 1598 | 0.480 |
Why?
|
Cyclopentanes | 2 | 2024 | 45 | 0.460 |
Why?
|
Education, Professional | 1 | 2013 | 13 | 0.460 |
Why?
|
Urinary Catheterization | 2 | 2013 | 121 | 0.450 |
Why?
|
Anesthesiology | 3 | 2022 | 149 | 0.450 |
Why?
|
Voice Disorders | 1 | 2013 | 39 | 0.450 |
Why?
|
Vocal Cords | 1 | 2013 | 94 | 0.430 |
Why?
|
Rheumatic Heart Disease | 3 | 2019 | 47 | 0.430 |
Why?
|
Cognition | 5 | 2022 | 1001 | 0.420 |
Why?
|
Arachis | 3 | 2022 | 69 | 0.420 |
Why?
|
Neoplasms | 15 | 2024 | 15696 | 0.420 |
Why?
|
Neuroblastoma | 4 | 2023 | 695 | 0.420 |
Why?
|
Internship and Residency | 5 | 2024 | 1475 | 0.420 |
Why?
|
Liver Diseases | 3 | 2023 | 594 | 0.420 |
Why?
|
Diabetic Ketoacidosis | 2 | 2024 | 151 | 0.420 |
Why?
|
Infant | 32 | 2023 | 13785 | 0.410 |
Why?
|
Parents | 10 | 2022 | 1041 | 0.410 |
Why?
|
Young Adult | 33 | 2024 | 22102 | 0.390 |
Why?
|
Resource Allocation | 1 | 2011 | 68 | 0.390 |
Why?
|
Pyridines | 4 | 2021 | 1289 | 0.380 |
Why?
|
Acetylcysteine | 2 | 2023 | 147 | 0.380 |
Why?
|
Astronauts | 1 | 2011 | 63 | 0.380 |
Why?
|
Occupational Health | 1 | 2011 | 96 | 0.380 |
Why?
|
Anti-Bacterial Agents | 4 | 2019 | 3091 | 0.380 |
Why?
|
Hemorrhagic Disorders | 2 | 2022 | 52 | 0.380 |
Why?
|
Truth Disclosure | 3 | 2018 | 187 | 0.370 |
Why?
|
von Willebrand Diseases | 2 | 2022 | 61 | 0.370 |
Why?
|
Health Status Indicators | 1 | 2011 | 223 | 0.360 |
Why?
|
Menorrhagia | 2 | 2022 | 75 | 0.360 |
Why?
|
Spinal Cord Injuries | 1 | 2013 | 340 | 0.360 |
Why?
|
Space Flight | 1 | 2011 | 160 | 0.340 |
Why?
|
Rhabdomyosarcoma | 2 | 2023 | 346 | 0.340 |
Why?
|
Drug Resistance, Neoplasm | 9 | 2024 | 5292 | 0.330 |
Why?
|
Quality of Life | 9 | 2023 | 4720 | 0.330 |
Why?
|
Urinary Tract Infections | 1 | 2013 | 332 | 0.330 |
Why?
|
Health Behavior | 1 | 2013 | 621 | 0.330 |
Why?
|
Sarcoma, Ewing | 3 | 2022 | 418 | 0.320 |
Why?
|
Simulation Training | 2 | 2023 | 161 | 0.320 |
Why?
|
Craniospinal Irradiation | 2 | 2021 | 131 | 0.320 |
Why?
|
Diabetic Retinopathy | 2 | 2021 | 179 | 0.320 |
Why?
|
Brain Neoplasms | 6 | 2022 | 4995 | 0.320 |
Why?
|
Asthma | 3 | 2023 | 904 | 0.320 |
Why?
|
Anemia, Sickle Cell | 2 | 2024 | 364 | 0.310 |
Why?
|
Monte Carlo Method | 1 | 2011 | 694 | 0.310 |
Why?
|
Kidney Failure, Chronic | 4 | 2018 | 983 | 0.300 |
Why?
|
Allergens | 4 | 2021 | 251 | 0.300 |
Why?
|
Pilot Projects | 11 | 2024 | 2858 | 0.300 |
Why?
|
Staphylococcus aureus | 3 | 2020 | 559 | 0.290 |
Why?
|
Professional Competence | 2 | 2018 | 142 | 0.290 |
Why?
|
Psychometrics | 3 | 2021 | 962 | 0.290 |
Why?
|
Tonsillectomy | 2 | 2021 | 111 | 0.290 |
Why?
|
Aortic Aneurysm | 3 | 2014 | 233 | 0.290 |
Why?
|
Heart Arrest | 2 | 2023 | 372 | 0.280 |
Why?
|
Cystic Fibrosis | 2 | 2023 | 274 | 0.280 |
Why?
|
Pyrazoles | 4 | 2021 | 1517 | 0.280 |
Why?
|
Hydrocortisone | 3 | 2018 | 389 | 0.280 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 16258 | 0.280 |
Why?
|
Anxiety | 1 | 2013 | 1241 | 0.270 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 3 | 2020 | 393 | 0.270 |
Why?
|
Echocardiography, Doppler, Color | 2 | 2016 | 126 | 0.270 |
Why?
|
Self Report | 5 | 2022 | 782 | 0.260 |
Why?
|
Salvage Therapy | 3 | 2019 | 2095 | 0.260 |
Why?
|
Adult | 40 | 2024 | 80607 | 0.260 |
Why?
|
Induction Chemotherapy | 2 | 2020 | 666 | 0.260 |
Why?
|
Physician-Patient Relations | 2 | 2024 | 807 | 0.260 |
Why?
|
Prospective Studies | 16 | 2022 | 13274 | 0.250 |
Why?
|
Urea Cycle Disorders, Inborn | 2 | 2023 | 79 | 0.250 |
Why?
|
Vaccines | 2 | 2021 | 405 | 0.250 |
Why?
|
Socioeconomic Factors | 6 | 2020 | 1263 | 0.250 |
Why?
|
Drug Resistant Epilepsy | 2 | 2018 | 200 | 0.250 |
Why?
|
Glutathione Transferase | 1 | 2006 | 367 | 0.250 |
Why?
|
Curriculum | 6 | 2023 | 903 | 0.250 |
Why?
|
Cardiopulmonary Resuscitation | 2 | 2019 | 326 | 0.240 |
Why?
|
Pregnancy Complications, Infectious | 4 | 2019 | 442 | 0.240 |
Why?
|
Protein Kinase Inhibitors | 6 | 2021 | 4884 | 0.240 |
Why?
|
Telemedicine | 2 | 2022 | 536 | 0.240 |
Why?
|
Hospitals, Pediatric | 6 | 2019 | 790 | 0.240 |
Why?
|
Vaccination | 3 | 2021 | 1175 | 0.230 |
Why?
|
Retrospective Studies | 30 | 2024 | 39468 | 0.230 |
Why?
|
Heart-Assist Devices | 3 | 2018 | 1207 | 0.220 |
Why?
|
Phenylbutyrates | 1 | 2023 | 62 | 0.220 |
Why?
|
Staphylococcal Infections | 3 | 2013 | 675 | 0.220 |
Why?
|
Self-Help Devices | 1 | 2022 | 14 | 0.210 |
Why?
|
Pain, Postoperative | 3 | 2013 | 641 | 0.210 |
Why?
|
Pneumococcal Vaccines | 1 | 2024 | 174 | 0.210 |
Why?
|
Killer Cells, Natural | 2 | 2019 | 931 | 0.210 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2024 | 1427 | 0.210 |
Why?
|
Craniopharyngioma | 1 | 2023 | 56 | 0.210 |
Why?
|
Cholecystectomy, Laparoscopic | 2 | 2013 | 75 | 0.210 |
Why?
|
Diabetes Mellitus | 2 | 2021 | 1121 | 0.210 |
Why?
|
Glutathione | 2 | 2023 | 369 | 0.210 |
Why?
|
Alagille Syndrome | 1 | 2022 | 46 | 0.210 |
Why?
|
Glycine | 2 | 2023 | 305 | 0.210 |
Why?
|
Skin Tests | 2 | 2019 | 98 | 0.210 |
Why?
|
Communication | 5 | 2024 | 908 | 0.200 |
Why?
|
Cell Phone | 1 | 2022 | 45 | 0.200 |
Why?
|
Health Personnel | 2 | 2020 | 649 | 0.200 |
Why?
|
Patient Compliance | 3 | 2019 | 685 | 0.200 |
Why?
|
Pediatrics | 3 | 2016 | 1186 | 0.190 |
Why?
|
Caregivers | 3 | 2017 | 729 | 0.190 |
Why?
|
Pyrimidines | 2 | 2024 | 3603 | 0.190 |
Why?
|
Disabled Persons | 1 | 2022 | 123 | 0.190 |
Why?
|
Health Literacy | 1 | 2022 | 121 | 0.190 |
Why?
|
Surveys and Questionnaires | 9 | 2021 | 5916 | 0.190 |
Why?
|
Time Factors | 14 | 2019 | 13253 | 0.190 |
Why?
|
Self-Management | 2 | 2020 | 94 | 0.190 |
Why?
|
Sleep Apnea Syndromes | 1 | 2022 | 86 | 0.190 |
Why?
|
Seizures | 2 | 2017 | 999 | 0.190 |
Why?
|
Pituitary Neoplasms | 1 | 2023 | 211 | 0.190 |
Why?
|
Hypoplastic Left Heart Syndrome | 2 | 2014 | 249 | 0.180 |
Why?
|
Polymorphism, Genetic | 1 | 2006 | 1470 | 0.180 |
Why?
|
Educational Measurement | 3 | 2018 | 410 | 0.180 |
Why?
|
Follow-Up Studies | 14 | 2020 | 15189 | 0.180 |
Why?
|
Clinical Competence | 7 | 2024 | 1359 | 0.180 |
Why?
|
Aspartate Aminotransferases | 2 | 2023 | 155 | 0.180 |
Why?
|
Cholestasis | 1 | 2022 | 206 | 0.180 |
Why?
|
Checklist | 2 | 2019 | 131 | 0.180 |
Why?
|
Liver Glycogen | 1 | 2020 | 27 | 0.180 |
Why?
|
Anesthesia, Caudal | 1 | 2020 | 16 | 0.180 |
Why?
|
Texas | 12 | 2021 | 6457 | 0.180 |
Why?
|
Muscle Strength | 1 | 2021 | 112 | 0.180 |
Why?
|
Insulin Resistance | 2 | 2023 | 744 | 0.180 |
Why?
|
Decision Support Techniques | 2 | 2018 | 637 | 0.180 |
Why?
|
Blood Glucose | 3 | 2022 | 1269 | 0.180 |
Why?
|
Adhesins, Bacterial | 1 | 2020 | 84 | 0.180 |
Why?
|
HIV Infections | 3 | 2019 | 2219 | 0.170 |
Why?
|
Biomarkers | 7 | 2023 | 5172 | 0.170 |
Why?
|
House Calls | 1 | 2020 | 40 | 0.170 |
Why?
|
Elasticity Imaging Techniques | 1 | 2022 | 189 | 0.170 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2021 | 241 | 0.170 |
Why?
|
Salmonella Infections | 1 | 2019 | 40 | 0.170 |
Why?
|
Knowledge | 1 | 2019 | 54 | 0.170 |
Why?
|
Argininosuccinate Lyase | 1 | 2020 | 63 | 0.170 |
Why?
|
Tomography, Optical Coherence | 2 | 2021 | 564 | 0.170 |
Why?
|
Treatment Outcome | 19 | 2023 | 34185 | 0.170 |
Why?
|
Brain Edema | 1 | 2020 | 87 | 0.170 |
Why?
|
Genes, Bacterial | 1 | 2020 | 239 | 0.170 |
Why?
|
Postpartum Hemorrhage | 1 | 2020 | 87 | 0.170 |
Why?
|
Models, Educational | 1 | 2019 | 96 | 0.170 |
Why?
|
Hydroxyurea | 1 | 2020 | 212 | 0.170 |
Why?
|
Neutropenia | 2 | 2021 | 987 | 0.170 |
Why?
|
Length of Stay | 2 | 2019 | 2032 | 0.170 |
Why?
|
Intelligence | 2 | 2019 | 133 | 0.170 |
Why?
|
Antineoplastic Agents, Immunological | 2 | 2020 | 1313 | 0.170 |
Why?
|
Computer-Assisted Instruction | 1 | 2019 | 86 | 0.170 |
Why?
|
Disinfection | 2 | 2022 | 39 | 0.170 |
Why?
|
Adenoidectomy | 2 | 2021 | 66 | 0.160 |
Why?
|
Webcasts as Topic | 1 | 2018 | 9 | 0.160 |
Why?
|
Syphilis, Congenital | 1 | 2019 | 26 | 0.160 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2020 | 267 | 0.160 |
Why?
|
GABA Modulators | 1 | 2018 | 15 | 0.160 |
Why?
|
Anaphylaxis | 2 | 2017 | 123 | 0.160 |
Why?
|
Schools | 2 | 2017 | 240 | 0.160 |
Why?
|
Videotape Recording | 1 | 2018 | 78 | 0.160 |
Why?
|
Pentobarbital | 1 | 2018 | 29 | 0.160 |
Why?
|
Mobile Applications | 1 | 2020 | 111 | 0.160 |
Why?
|
Intensive Care Units, Neonatal | 2 | 2018 | 286 | 0.160 |
Why?
|
Liver Transplantation | 2 | 2018 | 1161 | 0.160 |
Why?
|
Biofilms | 1 | 2020 | 202 | 0.160 |
Why?
|
Patient-Centered Care | 2 | 2020 | 317 | 0.160 |
Why?
|
Blood Group Incompatibility | 1 | 2018 | 34 | 0.160 |
Why?
|
Cross-Sectional Studies | 8 | 2024 | 4532 | 0.160 |
Why?
|
Hyperkalemia | 1 | 2019 | 81 | 0.160 |
Why?
|
Penicillins | 1 | 2019 | 150 | 0.160 |
Why?
|
Syphilis | 1 | 2019 | 65 | 0.160 |
Why?
|
Polymers | 1 | 2019 | 228 | 0.160 |
Why?
|
Steroids | 1 | 2020 | 355 | 0.150 |
Why?
|
Pyrazines | 1 | 2021 | 508 | 0.150 |
Why?
|
Oxidative Stress | 2 | 2023 | 1158 | 0.150 |
Why?
|
Cerebellar Neoplasms | 1 | 2023 | 469 | 0.150 |
Why?
|
Prevalence | 7 | 2024 | 3396 | 0.150 |
Why?
|
Postoperative Complications | 7 | 2021 | 5826 | 0.150 |
Why?
|
ABO Blood-Group System | 1 | 2018 | 130 | 0.150 |
Why?
|
Ketones | 1 | 2018 | 56 | 0.150 |
Why?
|
Computer Systems | 2 | 2020 | 109 | 0.150 |
Why?
|
Furans | 1 | 2018 | 106 | 0.150 |
Why?
|
Memory, Short-Term | 1 | 2019 | 168 | 0.150 |
Why?
|
Critical Pathways | 1 | 2019 | 155 | 0.150 |
Why?
|
Mass Screening | 2 | 2016 | 1568 | 0.150 |
Why?
|
Retina | 1 | 2021 | 548 | 0.150 |
Why?
|
Neoplasms, Second Primary | 1 | 2006 | 1377 | 0.150 |
Why?
|
Protons | 2 | 2022 | 476 | 0.150 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2017 | 22 | 0.150 |
Why?
|
Infant, Newborn | 11 | 2019 | 8544 | 0.150 |
Why?
|
Medulloblastoma | 1 | 2023 | 571 | 0.150 |
Why?
|
Walk Test | 1 | 2017 | 44 | 0.150 |
Why?
|
School Nursing | 1 | 2017 | 7 | 0.150 |
Why?
|
Prosthesis-Related Infections | 1 | 2020 | 246 | 0.150 |
Why?
|
Patient Handoff | 1 | 2018 | 42 | 0.150 |
Why?
|
Severity of Illness Index | 8 | 2023 | 4462 | 0.150 |
Why?
|
Vaccination Refusal | 1 | 2017 | 16 | 0.150 |
Why?
|
Cross Infection | 1 | 2022 | 550 | 0.150 |
Why?
|
Civil Defense | 1 | 2017 | 13 | 0.150 |
Why?
|
Age Factors | 8 | 2021 | 5497 | 0.150 |
Why?
|
Enterocolitis | 1 | 2017 | 47 | 0.150 |
Why?
|
Simian virus 40 | 1 | 2018 | 135 | 0.150 |
Why?
|
Glucose | 1 | 2023 | 1267 | 0.150 |
Why?
|
Airway Management | 1 | 2018 | 105 | 0.150 |
Why?
|
Medical Order Entry Systems | 1 | 2019 | 125 | 0.150 |
Why?
|
Risk Factors | 13 | 2023 | 18238 | 0.150 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2020 | 759 | 0.140 |
Why?
|
Interpersonal Relations | 2 | 2017 | 280 | 0.140 |
Why?
|
Renal Replacement Therapy | 1 | 2018 | 152 | 0.140 |
Why?
|
Adrenal Cortex Hormones | 2 | 2019 | 558 | 0.140 |
Why?
|
Nurse's Role | 1 | 2017 | 43 | 0.140 |
Why?
|
Pyrrolidinones | 1 | 2017 | 59 | 0.140 |
Why?
|
Irritable Bowel Syndrome | 1 | 2020 | 206 | 0.140 |
Why?
|
Autistic Disorder | 1 | 2020 | 334 | 0.140 |
Why?
|
Diet Therapy | 1 | 2017 | 54 | 0.140 |
Why?
|
Fathers | 1 | 2017 | 72 | 0.140 |
Why?
|
Electrocorticography | 1 | 2017 | 76 | 0.140 |
Why?
|
Insulin | 2 | 2022 | 1474 | 0.140 |
Why?
|
Status Epilepticus | 1 | 2018 | 150 | 0.140 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 2847 | 0.140 |
Why?
|
Liver Cirrhosis | 3 | 2023 | 1008 | 0.140 |
Why?
|
Hospitalization | 2 | 2024 | 2209 | 0.140 |
Why?
|
Photons | 2 | 2021 | 517 | 0.140 |
Why?
|
Anesthetics, Intravenous | 2 | 2014 | 74 | 0.140 |
Why?
|
Disaster Planning | 1 | 2017 | 67 | 0.140 |
Why?
|
Ultrasonography, Interventional | 1 | 2020 | 451 | 0.140 |
Why?
|
Anesthetics, Inhalation | 2 | 2014 | 63 | 0.140 |
Why?
|
Voice Training | 1 | 2016 | 5 | 0.140 |
Why?
|
Phonation | 1 | 2016 | 9 | 0.140 |
Why?
|
Bacterial Infections | 1 | 2020 | 484 | 0.140 |
Why?
|
Intraoperative Care | 1 | 2018 | 271 | 0.140 |
Why?
|
Rheumatic Diseases | 1 | 2017 | 96 | 0.140 |
Why?
|
Lymphoma, B-Cell | 1 | 2023 | 917 | 0.140 |
Why?
|
Cardiologists | 1 | 2016 | 39 | 0.140 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 33 | 0.140 |
Why?
|
Developmental Disabilities | 1 | 2021 | 684 | 0.140 |
Why?
|
Voice Quality | 1 | 2016 | 33 | 0.140 |
Why?
|
Malawi | 4 | 2019 | 380 | 0.130 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2023 | 1787 | 0.130 |
Why?
|
Learning | 1 | 2019 | 418 | 0.130 |
Why?
|
Air Ambulances | 1 | 2016 | 29 | 0.130 |
Why?
|
Medical Errors | 1 | 2018 | 223 | 0.130 |
Why?
|
Intelligence Tests | 1 | 2016 | 90 | 0.130 |
Why?
|
Hematologic Diseases | 1 | 2017 | 245 | 0.130 |
Why?
|
Dietary Proteins | 1 | 2017 | 247 | 0.130 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2016 | 68 | 0.130 |
Why?
|
Anemia | 1 | 2022 | 728 | 0.130 |
Why?
|
Cardiotonic Agents | 1 | 2017 | 159 | 0.130 |
Why?
|
United States | 10 | 2022 | 16312 | 0.130 |
Why?
|
Anilides | 1 | 2018 | 287 | 0.130 |
Why?
|
Cardiopulmonary Bypass | 1 | 2018 | 430 | 0.130 |
Why?
|
Shellfish Hypersensitivity | 1 | 2015 | 5 | 0.130 |
Why?
|
Reproducibility of Results | 7 | 2021 | 6192 | 0.130 |
Why?
|
Emergency Medical Technicians | 1 | 2016 | 43 | 0.130 |
Why?
|
Self-Injurious Behavior | 1 | 2016 | 56 | 0.130 |
Why?
|
Shellfish | 1 | 2015 | 24 | 0.130 |
Why?
|
Myocardial Contraction | 1 | 2017 | 303 | 0.130 |
Why?
|
School Health Services | 1 | 2016 | 110 | 0.130 |
Why?
|
Heart Defects, Congenital | 3 | 2018 | 1772 | 0.130 |
Why?
|
Vasodilator Agents | 1 | 2017 | 234 | 0.130 |
Why?
|
Administration, Oral | 4 | 2021 | 1583 | 0.130 |
Why?
|
Benzamides | 1 | 2021 | 1873 | 0.130 |
Why?
|
Device Removal | 2 | 2017 | 355 | 0.120 |
Why?
|
RNA, Viral | 1 | 2018 | 690 | 0.120 |
Why?
|
Drug Utilization | 1 | 2016 | 184 | 0.120 |
Why?
|
Informed Consent | 1 | 2018 | 432 | 0.120 |
Why?
|
Gastrointestinal Diseases | 1 | 2020 | 597 | 0.120 |
Why?
|
Larynx | 1 | 2016 | 140 | 0.120 |
Why?
|
Patient Education as Topic | 1 | 2020 | 766 | 0.120 |
Why?
|
Patient Readmission | 2 | 2019 | 595 | 0.120 |
Why?
|
Pneumonia, Bacterial | 1 | 2016 | 133 | 0.120 |
Why?
|
Basement Membrane | 1 | 2015 | 142 | 0.120 |
Why?
|
Cell Cycle Proteins | 2 | 2023 | 2099 | 0.120 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2015 | 63 | 0.120 |
Why?
|
Chronic Disease | 4 | 2023 | 1856 | 0.120 |
Why?
|
Guideline Adherence | 2 | 2018 | 653 | 0.120 |
Why?
|
Lupus Nephritis | 1 | 2015 | 57 | 0.120 |
Why?
|
Community Health Services | 1 | 2016 | 131 | 0.120 |
Why?
|
Cardiac Catheterization | 1 | 2019 | 749 | 0.120 |
Why?
|
Lymphoma | 1 | 2023 | 1495 | 0.120 |
Why?
|
Respiration Disorders | 1 | 2014 | 47 | 0.120 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2017 | 242 | 0.120 |
Why?
|
Waiting Lists | 1 | 2016 | 275 | 0.120 |
Why?
|
Ulna | 1 | 2014 | 10 | 0.120 |
Why?
|
Fentanyl | 2 | 2013 | 154 | 0.120 |
Why?
|
Middle Aged | 20 | 2021 | 89424 | 0.120 |
Why?
|
Feasibility Studies | 4 | 2023 | 2364 | 0.120 |
Why?
|
Inflammation | 2 | 2023 | 2568 | 0.120 |
Why?
|
Wrist Joint | 1 | 2014 | 30 | 0.120 |
Why?
|
End Stage Liver Disease | 1 | 2016 | 186 | 0.120 |
Why?
|
Tissue Inhibitor of Metalloproteinases | 1 | 2014 | 43 | 0.120 |
Why?
|
Radius | 1 | 2014 | 43 | 0.120 |
Why?
|
Pollen | 1 | 2014 | 47 | 0.120 |
Why?
|
Lost to Follow-Up | 1 | 2014 | 34 | 0.120 |
Why?
|
Hypoglycemic Agents | 1 | 2019 | 609 | 0.120 |
Why?
|
Pregnancy | 8 | 2023 | 7821 | 0.120 |
Why?
|
Tracheostomy | 1 | 2017 | 253 | 0.120 |
Why?
|
Neurosurgical Procedures | 1 | 2019 | 638 | 0.120 |
Why?
|
Sodium Hypochlorite | 1 | 2013 | 12 | 0.120 |
Why?
|
Attitude to Health | 1 | 2017 | 467 | 0.120 |
Why?
|
Postnatal Care | 1 | 2014 | 48 | 0.120 |
Why?
|
Mothers | 1 | 2017 | 424 | 0.120 |
Why?
|
Baths | 1 | 2013 | 16 | 0.120 |
Why?
|
Registries | 6 | 2019 | 2278 | 0.120 |
Why?
|
Hypoxia-Ischemia, Brain | 1 | 2015 | 145 | 0.120 |
Why?
|
Reinforcement Schedule | 1 | 2013 | 26 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2017 | 424 | 0.120 |
Why?
|
Speech-Language Pathology | 1 | 2013 | 13 | 0.120 |
Why?
|
Airway Extubation | 1 | 2014 | 67 | 0.110 |
Why?
|
Hypothermia, Induced | 1 | 2015 | 183 | 0.110 |
Why?
|
Morphine | 2 | 2013 | 321 | 0.110 |
Why?
|
Hypoglycemia | 1 | 2015 | 215 | 0.110 |
Why?
|
Hygiene | 1 | 2013 | 30 | 0.110 |
Why?
|
Biliary Atresia | 1 | 2016 | 199 | 0.110 |
Why?
|
Education, Medical, Continuing | 1 | 2016 | 254 | 0.110 |
Why?
|
Cancer Survivors | 1 | 2021 | 723 | 0.110 |
Why?
|
Anti-Inflammatory Agents | 1 | 2017 | 471 | 0.110 |
Why?
|
Quinolines | 1 | 2017 | 396 | 0.110 |
Why?
|
Renal Dialysis | 3 | 2016 | 968 | 0.110 |
Why?
|
Community-Acquired Infections | 1 | 2016 | 290 | 0.110 |
Why?
|
Bacteremia | 1 | 2019 | 692 | 0.110 |
Why?
|
Disinfectants | 1 | 2013 | 36 | 0.110 |
Why?
|
Social Support | 1 | 2017 | 581 | 0.110 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2020 | 1053 | 0.110 |
Why?
|
Education, Medical, Graduate | 2 | 2024 | 709 | 0.110 |
Why?
|
Foreign Bodies | 1 | 2015 | 143 | 0.110 |
Why?
|
Matrix Metalloproteinases | 1 | 2014 | 143 | 0.110 |
Why?
|
Chromosome Disorders | 1 | 2016 | 420 | 0.110 |
Why?
|
Cognition Disorders | 1 | 2019 | 787 | 0.110 |
Why?
|
HIV Seronegativity | 1 | 2013 | 33 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2017 | 675 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2020 | 5028 | 0.110 |
Why?
|
Decision Making | 2 | 2018 | 1343 | 0.110 |
Why?
|
Fungi | 1 | 2014 | 144 | 0.110 |
Why?
|
Physicians | 2 | 2018 | 913 | 0.110 |
Why?
|
Antibodies, Monoclonal, Humanized | 3 | 2024 | 3362 | 0.110 |
Why?
|
Tissue Distribution | 3 | 2019 | 907 | 0.110 |
Why?
|
Drug Administration Schedule | 4 | 2020 | 3518 | 0.110 |
Why?
|
Office Visits | 1 | 2013 | 99 | 0.110 |
Why?
|
Proportional Hazards Models | 5 | 2017 | 5114 | 0.110 |
Why?
|
Fatigue | 2 | 2017 | 1267 | 0.110 |
Why?
|
Lymphocytes | 1 | 2018 | 1237 | 0.110 |
Why?
|
Intensive Care Units, Pediatric | 4 | 2018 | 461 | 0.110 |
Why?
|
Immunophenotyping | 1 | 2017 | 1700 | 0.110 |
Why?
|
Immunosuppressive Agents | 2 | 2018 | 1429 | 0.110 |
Why?
|
Ventricular Function, Left | 1 | 2017 | 614 | 0.110 |
Why?
|
NADPH Oxidases | 1 | 2013 | 147 | 0.110 |
Why?
|
Longitudinal Studies | 4 | 2020 | 2049 | 0.110 |
Why?
|
Hyperglycemia | 1 | 2015 | 338 | 0.110 |
Why?
|
Tympanic Membrane | 1 | 2012 | 18 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 2015 | 330 | 0.100 |
Why?
|
Sexual Partners | 1 | 2013 | 111 | 0.100 |
Why?
|
Sirolimus | 1 | 2017 | 834 | 0.100 |
Why?
|
Infant Mortality | 1 | 2013 | 192 | 0.100 |
Why?
|
Pre-Eclampsia | 1 | 2015 | 214 | 0.100 |
Why?
|
Palliative Care | 2 | 2014 | 2130 | 0.100 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2015 | 251 | 0.100 |
Why?
|
Body Composition | 1 | 2015 | 609 | 0.100 |
Why?
|
Otologic Surgical Procedures | 1 | 2012 | 35 | 0.100 |
Why?
|
Bacteriuria | 1 | 2013 | 82 | 0.100 |
Why?
|
Intraoperative Complications | 1 | 2014 | 308 | 0.100 |
Why?
|
Rituximab | 1 | 2017 | 1551 | 0.100 |
Why?
|
HIV Seropositivity | 1 | 2013 | 146 | 0.100 |
Why?
|
Antineoplastic Agents | 3 | 2021 | 14502 | 0.100 |
Why?
|
Marfan Syndrome | 1 | 2014 | 158 | 0.100 |
Why?
|
Reward | 1 | 2013 | 200 | 0.100 |
Why?
|
Recombinant Fusion Proteins | 1 | 2017 | 1595 | 0.100 |
Why?
|
Abdominal Muscles | 1 | 2012 | 71 | 0.100 |
Why?
|
Esophagus | 1 | 2015 | 557 | 0.100 |
Why?
|
Self Care | 1 | 2013 | 231 | 0.100 |
Why?
|
Anesthesia, Local | 1 | 2012 | 66 | 0.100 |
Why?
|
HIV | 1 | 2013 | 232 | 0.100 |
Why?
|
Continuity of Patient Care | 1 | 2014 | 227 | 0.100 |
Why?
|
Logistic Models | 5 | 2017 | 3520 | 0.100 |
Why?
|
Otolaryngology | 1 | 2013 | 137 | 0.100 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 625 | 0.100 |
Why?
|
Head | 1 | 2013 | 252 | 0.100 |
Why?
|
Autoantibodies | 1 | 2015 | 589 | 0.100 |
Why?
|
Multivariate Analysis | 5 | 2017 | 4385 | 0.100 |
Why?
|
Quality Improvement | 1 | 2019 | 922 | 0.100 |
Why?
|
Molecular Imaging | 1 | 2013 | 187 | 0.100 |
Why?
|
Hodgkin Disease | 1 | 2020 | 1458 | 0.100 |
Why?
|
Nerve Fibers | 2 | 2021 | 115 | 0.100 |
Why?
|
Green Fluorescent Proteins | 1 | 2013 | 701 | 0.090 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2018 | 646 | 0.090 |
Why?
|
Genes, Reporter | 1 | 2013 | 809 | 0.090 |
Why?
|
Cognitive Dysfunction | 1 | 2016 | 358 | 0.090 |
Why?
|
Single-Blind Method | 3 | 2020 | 418 | 0.090 |
Why?
|
Diagnostic Errors | 1 | 2015 | 518 | 0.090 |
Why?
|
Cocaine-Related Disorders | 1 | 2013 | 237 | 0.090 |
Why?
|
Desensitization, Immunologic | 2 | 2022 | 103 | 0.090 |
Why?
|
Head and Neck Neoplasms | 1 | 2006 | 4073 | 0.090 |
Why?
|
Medication Adherence | 1 | 2015 | 521 | 0.090 |
Why?
|
Anesthetics, Local | 1 | 2012 | 170 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2018 | 792 | 0.090 |
Why?
|
Neurodevelopmental Disorders | 1 | 2015 | 441 | 0.090 |
Why?
|
Perioperative Care | 1 | 2014 | 460 | 0.090 |
Why?
|
Poverty | 1 | 2014 | 498 | 0.090 |
Why?
|
Disease Management | 1 | 2016 | 1105 | 0.090 |
Why?
|
Premature Birth | 1 | 2015 | 420 | 0.090 |
Why?
|
Child Behavior | 1 | 2012 | 248 | 0.090 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2006 | 5531 | 0.090 |
Why?
|
Bone Neoplasms | 2 | 2019 | 2652 | 0.090 |
Why?
|
Prognosis | 8 | 2020 | 22229 | 0.090 |
Why?
|
Fellowships and Scholarships | 1 | 2014 | 412 | 0.090 |
Why?
|
Diabetes Complications | 1 | 2012 | 321 | 0.090 |
Why?
|
Incidence | 5 | 2019 | 5890 | 0.090 |
Why?
|
Glioma | 1 | 2021 | 2001 | 0.090 |
Why?
|
Aorta | 1 | 2013 | 707 | 0.080 |
Why?
|
Heart Failure | 3 | 2018 | 2658 | 0.080 |
Why?
|
Kidney Transplantation | 1 | 2015 | 785 | 0.080 |
Why?
|
Prenatal Diagnosis | 1 | 2013 | 595 | 0.080 |
Why?
|
Immunoglobulin M | 2 | 2024 | 354 | 0.080 |
Why?
|
Terminal Care | 1 | 2014 | 463 | 0.080 |
Why?
|
Practice Patterns, Physicians' | 1 | 2018 | 1347 | 0.080 |
Why?
|
Thoracic Surgery | 1 | 2013 | 304 | 0.080 |
Why?
|
Aorta, Thoracic | 1 | 2014 | 572 | 0.080 |
Why?
|
von Willebrand Factor | 2 | 2022 | 353 | 0.080 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 956 | 0.080 |
Why?
|
Sleep | 2 | 2022 | 430 | 0.080 |
Why?
|
Intellectual Disability | 1 | 2016 | 1040 | 0.080 |
Why?
|
Tertiary Care Centers | 3 | 2017 | 421 | 0.080 |
Why?
|
Membrane Glycoproteins | 1 | 2013 | 1097 | 0.080 |
Why?
|
United Kingdom | 2 | 2021 | 281 | 0.080 |
Why?
|
Linear Models | 3 | 2017 | 1105 | 0.080 |
Why?
|
Pneumonia, Viral | 1 | 2016 | 723 | 0.080 |
Why?
|
Adrenergic beta-Agonists | 2 | 2019 | 138 | 0.080 |
Why?
|
Administration, Intravenous | 2 | 2019 | 254 | 0.070 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2014 | 618 | 0.070 |
Why?
|
Intubation, Intratracheal | 1 | 2012 | 459 | 0.070 |
Why?
|
Dietary Supplements | 2 | 2023 | 585 | 0.070 |
Why?
|
Asymptomatic Diseases | 2 | 2019 | 104 | 0.070 |
Why?
|
Cardiac Surgical Procedures | 1 | 2017 | 1272 | 0.070 |
Why?
|
Brain Injuries | 1 | 2013 | 751 | 0.070 |
Why?
|
Immunoglobulin E | 2 | 2019 | 170 | 0.070 |
Why?
|
Potassium | 2 | 2019 | 331 | 0.070 |
Why?
|
Odds Ratio | 2 | 2015 | 2361 | 0.070 |
Why?
|
Biopsy | 3 | 2023 | 3486 | 0.070 |
Why?
|
Cohort Studies | 4 | 2023 | 9480 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2015 | 817 | 0.070 |
Why?
|
Kidney | 1 | 2015 | 2196 | 0.070 |
Why?
|
Aged | 10 | 2023 | 72809 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 3 | 2017 | 7960 | 0.070 |
Why?
|
Isotretinoin | 1 | 2006 | 158 | 0.070 |
Why?
|
Chromosome Breakage | 1 | 2006 | 226 | 0.070 |
Why?
|
Analgesics, Opioid | 2 | 2013 | 1425 | 0.070 |
Why?
|
Canada | 2 | 2017 | 448 | 0.060 |
Why?
|
Atherosclerosis | 1 | 2013 | 970 | 0.060 |
Why?
|
Mutagens | 1 | 2006 | 186 | 0.060 |
Why?
|
Nuclear Family | 1 | 2005 | 55 | 0.060 |
Why?
|
Bleomycin | 1 | 2006 | 478 | 0.060 |
Why?
|
Chemoprevention | 1 | 2006 | 250 | 0.060 |
Why?
|
Mitochondria | 2 | 2023 | 1307 | 0.060 |
Why?
|
NEDD8 Protein | 1 | 2024 | 25 | 0.060 |
Why?
|
Time-to-Treatment | 2 | 2020 | 314 | 0.060 |
Why?
|
Anti-Retroviral Agents | 2 | 2017 | 153 | 0.060 |
Why?
|
Penetrance | 1 | 2005 | 134 | 0.060 |
Why?
|
MicroRNAs | 1 | 2018 | 2954 | 0.060 |
Why?
|
Methyl Ethers | 2 | 2014 | 29 | 0.060 |
Why?
|
Observer Variation | 2 | 2017 | 708 | 0.060 |
Why?
|
Pain Measurement | 3 | 2013 | 995 | 0.060 |
Why?
|
B-Lymphocyte Subsets | 1 | 2024 | 49 | 0.060 |
Why?
|
Brain | 1 | 2017 | 4186 | 0.060 |
Why?
|
Predictive Value of Tests | 3 | 2017 | 5030 | 0.060 |
Why?
|
Risk Assessment | 4 | 2017 | 7164 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 7062 | 0.060 |
Why?
|
Propofol | 2 | 2014 | 80 | 0.060 |
Why?
|
Aging | 2 | 2023 | 1578 | 0.060 |
Why?
|
Recurrence | 3 | 2017 | 4875 | 0.060 |
Why?
|
Genetic Linkage | 1 | 2005 | 516 | 0.060 |
Why?
|
Endoglin | 1 | 2022 | 43 | 0.050 |
Why?
|
Matrix Metalloproteinase 7 | 1 | 2022 | 34 | 0.050 |
Why?
|
Transcription Factor 7-Like 2 Protein | 1 | 2022 | 41 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 2006 | 599 | 0.050 |
Why?
|
Insulin-Secreting Cells | 1 | 2024 | 165 | 0.050 |
Why?
|
Information Seeking Behavior | 1 | 2022 | 34 | 0.050 |
Why?
|
Snoring | 1 | 2021 | 12 | 0.050 |
Why?
|
Blindness | 1 | 2022 | 78 | 0.050 |
Why?
|
Pneumococcal Infections | 1 | 2024 | 264 | 0.050 |
Why?
|
Emergencies | 1 | 2023 | 207 | 0.050 |
Why?
|
Echocardiography | 2 | 2019 | 1261 | 0.050 |
Why?
|
Spleen | 1 | 2024 | 692 | 0.050 |
Why?
|
Social Adjustment | 1 | 2022 | 113 | 0.050 |
Why?
|
Emergency Service, Hospital | 2 | 2020 | 1217 | 0.050 |
Why?
|
Survival Rate | 3 | 2020 | 12429 | 0.050 |
Why?
|
Comorbidity | 2 | 2020 | 2454 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6269 | 0.050 |
Why?
|
Glycine Agents | 1 | 2021 | 14 | 0.050 |
Why?
|
Immunoglobulin G | 2 | 2015 | 1060 | 0.050 |
Why?
|
Reoperation | 2 | 2018 | 1446 | 0.050 |
Why?
|
Drug Therapy, Combination | 2 | 2018 | 2346 | 0.050 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 77 | 0.050 |
Why?
|
Resuscitation | 1 | 2023 | 248 | 0.050 |
Why?
|
Free Radical Scavengers | 1 | 2021 | 83 | 0.050 |
Why?
|
Checkpoint Kinase 2 | 1 | 2021 | 130 | 0.050 |
Why?
|
Prenatal Care | 2 | 2014 | 331 | 0.050 |
Why?
|
Polysomnography | 1 | 2022 | 165 | 0.050 |
Why?
|
Antigens, CD | 2 | 2018 | 1409 | 0.050 |
Why?
|
Leukopenia | 1 | 2021 | 149 | 0.050 |
Why?
|
Triglycerides | 1 | 2023 | 621 | 0.050 |
Why?
|
Disease Progression | 3 | 2019 | 6888 | 0.050 |
Why?
|
Endothelium | 1 | 2021 | 163 | 0.050 |
Why?
|
Palpation | 1 | 2020 | 52 | 0.050 |
Why?
|
Biological Availability | 1 | 2020 | 223 | 0.040 |
Why?
|
Interleukin-8 | 1 | 2022 | 529 | 0.040 |
Why?
|
Checkpoint Kinase 1 | 1 | 2021 | 180 | 0.040 |
Why?
|
Retinal Ganglion Cells | 1 | 2021 | 153 | 0.040 |
Why?
|
Pragmatic Clinical Trials as Topic | 1 | 2020 | 26 | 0.040 |
Why?
|
Monosaccharides | 1 | 2020 | 27 | 0.040 |
Why?
|
Case-Control Studies | 3 | 2015 | 6243 | 0.040 |
Why?
|
Body Weight | 2 | 2015 | 1321 | 0.040 |
Why?
|
Point-of-Care Systems | 1 | 2022 | 216 | 0.040 |
Why?
|
Triticum | 1 | 2019 | 32 | 0.040 |
Why?
|
Fermentation | 1 | 2020 | 67 | 0.040 |
Why?
|
Eggs | 1 | 2019 | 26 | 0.040 |
Why?
|
Topotecan | 1 | 2020 | 241 | 0.040 |
Why?
|
Algorithms | 1 | 2011 | 3983 | 0.040 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 161 | 0.040 |
Why?
|
Needles | 1 | 2020 | 107 | 0.040 |
Why?
|
Oligosaccharides | 1 | 2020 | 111 | 0.040 |
Why?
|
Liver | 2 | 2022 | 2989 | 0.040 |
Why?
|
New Orleans | 1 | 2019 | 14 | 0.040 |
Why?
|
Fibrosis | 1 | 2023 | 804 | 0.040 |
Why?
|
Cell Survival | 2 | 2018 | 3061 | 0.040 |
Why?
|
Soft Tissue Infections | 1 | 2020 | 105 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 2020 | 240 | 0.040 |
Why?
|
Factor Analysis, Statistical | 1 | 2020 | 353 | 0.040 |
Why?
|
Geriatric Assessment | 1 | 2021 | 292 | 0.040 |
Why?
|
CD4-CD8 Ratio | 1 | 2019 | 58 | 0.040 |
Why?
|
Milk | 1 | 2019 | 122 | 0.040 |
Why?
|
Phenotype | 2 | 2022 | 6395 | 0.040 |
Why?
|
Respiratory Function Tests | 1 | 2020 | 333 | 0.040 |
Why?
|
Health Promotion | 1 | 2023 | 516 | 0.040 |
Why?
|
Self-Assessment | 1 | 2018 | 91 | 0.040 |
Why?
|
Achievement | 1 | 2018 | 41 | 0.040 |
Why?
|
Vidarabine | 1 | 2023 | 1362 | 0.040 |
Why?
|
Patient Simulation | 1 | 2018 | 44 | 0.040 |
Why?
|
Regulatory Sequences, Ribonucleic Acid | 1 | 2018 | 18 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2021 | 11816 | 0.040 |
Why?
|
Genotype | 1 | 2006 | 4166 | 0.040 |
Why?
|
Antigens, Polyomavirus Transforming | 1 | 2018 | 110 | 0.040 |
Why?
|
Ipilimumab | 1 | 2022 | 749 | 0.040 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2017 | 17 | 0.040 |
Why?
|
Cell Transformation, Viral | 1 | 2018 | 136 | 0.040 |
Why?
|
Aged, 80 and over | 4 | 2021 | 30768 | 0.040 |
Why?
|
Manikins | 1 | 2018 | 137 | 0.040 |
Why?
|
Orthopedics | 1 | 2018 | 76 | 0.040 |
Why?
|
Efficiency, Organizational | 1 | 2018 | 91 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2019 | 320 | 0.040 |
Why?
|
Phthalazines | 1 | 2019 | 260 | 0.040 |
Why?
|
Internet | 1 | 2022 | 730 | 0.040 |
Why?
|
Pregnancy, High-Risk | 1 | 2017 | 48 | 0.040 |
Why?
|
Hydrocephalus | 1 | 2020 | 239 | 0.040 |
Why?
|
Goals | 1 | 2019 | 193 | 0.040 |
Why?
|
CD56 Antigen | 1 | 2017 | 84 | 0.040 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2023 | 2273 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2024 | 1569 | 0.040 |
Why?
|
Social Workers | 1 | 2017 | 5 | 0.040 |
Why?
|
Specialization | 1 | 2018 | 133 | 0.040 |
Why?
|
Genome, Viral | 1 | 2018 | 167 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2022 | 747 | 0.040 |
Why?
|
Cytarabine | 1 | 2023 | 1993 | 0.040 |
Why?
|
Mice | 4 | 2023 | 35271 | 0.040 |
Why?
|
Microtubules | 1 | 2018 | 267 | 0.040 |
Why?
|
Azacitidine | 1 | 2023 | 1191 | 0.040 |
Why?
|
Hemorrhage | 1 | 2022 | 766 | 0.040 |
Why?
|
Epinephrine | 1 | 2018 | 256 | 0.040 |
Why?
|
Smoking | 1 | 2006 | 2523 | 0.040 |
Why?
|
Heart Rate | 1 | 2020 | 752 | 0.040 |
Why?
|
Administration, Topical | 1 | 2017 | 266 | 0.040 |
Why?
|
Lymphocyte Subsets | 1 | 2017 | 137 | 0.040 |
Why?
|
Emergency Medicine | 1 | 2018 | 146 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2017 | 87 | 0.030 |
Why?
|
Animals | 5 | 2023 | 60933 | 0.030 |
Why?
|
Stroboscopy | 1 | 2016 | 4 | 0.030 |
Why?
|
Sound Spectrography | 1 | 2016 | 8 | 0.030 |
Why?
|
Osteosarcoma | 1 | 2024 | 948 | 0.030 |
Why?
|
Epilepsies, Partial | 1 | 2017 | 114 | 0.030 |
Why?
|
Adolescent Behavior | 1 | 2019 | 234 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2017 | 134 | 0.030 |
Why?
|
Neurology | 1 | 2018 | 121 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 1432 | 0.030 |
Why?
|
Legionella | 1 | 2016 | 18 | 0.030 |
Why?
|
Respiratory Tract Diseases | 1 | 2017 | 115 | 0.030 |
Why?
|
Vincristine | 1 | 2020 | 1532 | 0.030 |
Why?
|
Myeloid Cells | 1 | 2018 | 276 | 0.030 |
Why?
|
Poliovirus Vaccines | 1 | 2016 | 15 | 0.030 |
Why?
|
Acoustics | 1 | 2016 | 43 | 0.030 |
Why?
|
Pneumocystis carinii | 1 | 2016 | 20 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 452 | 0.030 |
Why?
|
Pregnant Women | 1 | 2017 | 162 | 0.030 |
Why?
|
Survivors | 1 | 2022 | 1030 | 0.030 |
Why?
|
Haemophilus Vaccines | 1 | 2016 | 40 | 0.030 |
Why?
|
Chickenpox Vaccine | 1 | 2016 | 18 | 0.030 |
Why?
|
Exome | 1 | 2022 | 1272 | 0.030 |
Why?
|
Measles-Mumps-Rubella Vaccine | 1 | 2016 | 15 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 9323 | 0.030 |
Why?
|
Standard of Care | 1 | 2018 | 267 | 0.030 |
Why?
|
Comprehension | 1 | 2017 | 123 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2018 | 471 | 0.030 |
Why?
|
Potassium Radioisotopes | 1 | 2015 | 7 | 0.030 |
Why?
|
Hepatitis B Vaccines | 1 | 2016 | 52 | 0.030 |
Why?
|
Vomiting | 1 | 2017 | 357 | 0.030 |
Why?
|
Family | 1 | 2020 | 759 | 0.030 |
Why?
|
Wasting Syndrome | 1 | 2015 | 28 | 0.030 |
Why?
|
Medicaid | 1 | 2019 | 311 | 0.030 |
Why?
|
New Zealand | 1 | 2015 | 64 | 0.030 |
Why?
|
Lymphadenitis | 1 | 2015 | 40 | 0.030 |
Why?
|
Dendritic Cells | 1 | 2022 | 1117 | 0.030 |
Why?
|
Critical Care | 1 | 2022 | 803 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2021 | 872 | 0.030 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2016 | 37 | 0.030 |
Why?
|
Mice, Inbred MRL lpr | 1 | 2015 | 25 | 0.030 |
Why?
|
Apgar Score | 1 | 2015 | 56 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2017 | 489 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 619 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2018 | 311 | 0.030 |
Why?
|
Antibodies, Antinuclear | 1 | 2015 | 48 | 0.030 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2016 | 171 | 0.030 |
Why?
|
Sample Size | 1 | 2016 | 212 | 0.030 |
Why?
|
Failure to Thrive | 1 | 2015 | 99 | 0.030 |
Why?
|
Oligohydramnios | 1 | 2015 | 35 | 0.030 |
Why?
|
Stress, Physiological | 1 | 2018 | 501 | 0.030 |
Why?
|
Respiratory Distress Syndrome, Newborn | 1 | 2016 | 102 | 0.030 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2016 | 228 | 0.030 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2015 | 100 | 0.030 |
Why?
|
Biomechanical Phenomena | 1 | 2016 | 355 | 0.030 |
Why?
|
Infant, Small for Gestational Age | 1 | 2015 | 62 | 0.030 |
Why?
|
Pandemics | 1 | 2024 | 1627 | 0.030 |
Why?
|
General Surgery | 1 | 2018 | 344 | 0.030 |
Why?
|
Perinatal Death | 1 | 2015 | 31 | 0.030 |
Why?
|
Mycophenolic Acid | 1 | 2015 | 153 | 0.030 |
Why?
|
Dexamethasone | 1 | 2020 | 1471 | 0.030 |
Why?
|
Sex Distribution | 1 | 2016 | 510 | 0.030 |
Why?
|
Cross Reactions | 1 | 2015 | 271 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2017 | 1082 | 0.030 |
Why?
|
Cyclosporine | 1 | 2015 | 284 | 0.030 |
Why?
|
Skin | 1 | 2020 | 1284 | 0.030 |
Why?
|
Stroke Volume | 1 | 2017 | 604 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2017 | 707 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2020 | 7415 | 0.030 |
Why?
|
Platelet Count | 1 | 2015 | 494 | 0.030 |
Why?
|
Health Surveys | 1 | 2016 | 414 | 0.030 |
Why?
|
Immunoglobulin A | 1 | 2015 | 249 | 0.030 |
Why?
|
Creatinine | 1 | 2016 | 552 | 0.030 |
Why?
|
Age Distribution | 1 | 2016 | 715 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2006 | 10092 | 0.030 |
Why?
|
Education, Medical | 1 | 2018 | 359 | 0.030 |
Why?
|
Positive-Pressure Respiration | 1 | 2014 | 122 | 0.030 |
Why?
|
Aftercare | 1 | 2015 | 256 | 0.030 |
Why?
|
Operating Rooms | 1 | 2015 | 126 | 0.030 |
Why?
|
Glycosaminoglycans | 1 | 2013 | 62 | 0.030 |
Why?
|
Streptococcus pneumoniae | 1 | 2016 | 350 | 0.030 |
Why?
|
Tacrolimus | 1 | 2015 | 346 | 0.030 |
Why?
|
Elastic Tissue | 1 | 2013 | 34 | 0.030 |
Why?
|
Diarrhea | 1 | 2017 | 690 | 0.030 |
Why?
|
Graft Rejection | 1 | 2018 | 846 | 0.030 |
Why?
|
Elastin | 1 | 2013 | 52 | 0.030 |
Why?
|
Patient Safety | 1 | 2019 | 676 | 0.030 |
Why?
|
Patient Discharge | 1 | 2019 | 711 | 0.030 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2013 | 139 | 0.030 |
Why?
|
Prosthesis Design | 1 | 2017 | 792 | 0.030 |
Why?
|
Fetal Growth Retardation | 1 | 2015 | 204 | 0.030 |
Why?
|
NADPH Oxidase 2 | 1 | 2013 | 45 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 2733 | 0.030 |
Why?
|
Birth Weight | 1 | 2015 | 371 | 0.030 |
Why?
|
Echoencephalography | 1 | 2013 | 23 | 0.030 |
Why?
|
Asymptomatic Infections | 1 | 2013 | 33 | 0.030 |
Why?
|
Isoflurane | 1 | 2013 | 71 | 0.030 |
Why?
|
Substance Abuse Detection | 1 | 2013 | 65 | 0.030 |
Why?
|
Hospitals, County | 1 | 2013 | 29 | 0.030 |
Why?
|
Doxorubicin | 1 | 2020 | 3059 | 0.030 |
Why?
|
ROC Curve | 1 | 2016 | 1224 | 0.030 |
Why?
|
Southwestern United States | 1 | 2013 | 63 | 0.030 |
Why?
|
Extracellular Space | 1 | 2013 | 134 | 0.030 |
Why?
|
Risk | 1 | 2017 | 1998 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2020 | 3143 | 0.030 |
Why?
|
Macrophage Activation | 1 | 2013 | 147 | 0.030 |
Why?
|
DNA Damage | 1 | 2021 | 1987 | 0.030 |
Why?
|
Social Participation | 1 | 2012 | 23 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2016 | 556 | 0.030 |
Why?
|
Biosensing Techniques | 1 | 2013 | 77 | 0.030 |
Why?
|
CD3 Complex | 1 | 2013 | 316 | 0.030 |
Why?
|
Fluorescence | 1 | 2013 | 202 | 0.030 |
Why?
|
Prednisone | 1 | 2015 | 997 | 0.030 |
Why?
|
Muscle Fibers, Skeletal | 1 | 2013 | 121 | 0.030 |
Why?
|
Infant Behavior | 1 | 2012 | 13 | 0.030 |
Why?
|
Social Stigma | 1 | 2013 | 80 | 0.030 |
Why?
|
Anesthesia Recovery Period | 1 | 2012 | 36 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2006 | 5705 | 0.030 |
Why?
|
Postpartum Period | 1 | 2014 | 266 | 0.030 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2013 | 198 | 0.030 |
Why?
|
Glycemic Index | 1 | 2012 | 29 | 0.030 |
Why?
|
Recovery of Function | 1 | 2016 | 723 | 0.030 |
Why?
|
Nervous System Diseases | 1 | 2017 | 525 | 0.030 |
Why?
|
Research Design | 1 | 2020 | 1598 | 0.030 |
Why?
|
Patient Care Team | 1 | 2018 | 829 | 0.030 |
Why?
|
Hospital Mortality | 1 | 2018 | 1405 | 0.030 |
Why?
|
Cesarean Section | 1 | 2015 | 376 | 0.030 |
Why?
|
Electric Stimulation | 1 | 2013 | 442 | 0.030 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2014 | 240 | 0.030 |
Why?
|
Sex Factors | 1 | 2017 | 2215 | 0.030 |
Why?
|
Administration, Intranasal | 1 | 2012 | 201 | 0.030 |
Why?
|
Postoperative Period | 1 | 2014 | 673 | 0.030 |
Why?
|
Diet | 1 | 2020 | 1476 | 0.030 |
Why?
|
B-Lymphocytes | 1 | 2018 | 1347 | 0.030 |
Why?
|
Injections, Intramuscular | 1 | 2012 | 257 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 1506 | 0.020 |
Why?
|
Graft Survival | 1 | 2015 | 1094 | 0.020 |
Why?
|
Pedigree | 1 | 2016 | 1931 | 0.020 |
Why?
|
Chest Tubes | 1 | 2012 | 115 | 0.020 |
Why?
|
Influenza Vaccines | 1 | 2017 | 655 | 0.020 |
Why?
|
Surgical Instruments | 1 | 2012 | 139 | 0.020 |
Why?
|
Gestational Age | 1 | 2015 | 1082 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2016 | 1091 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2012 | 578 | 0.020 |
Why?
|
Heart Diseases | 1 | 2018 | 756 | 0.020 |
Why?
|
Body Image | 1 | 2012 | 139 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2013 | 729 | 0.020 |
Why?
|
Chromosome Deletion | 1 | 2016 | 1018 | 0.020 |
Why?
|
Viral Load | 1 | 2013 | 488 | 0.020 |
Why?
|
Surgeons | 1 | 2018 | 544 | 0.020 |
Why?
|
Self Concept | 1 | 2012 | 206 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 1354 | 0.020 |
Why?
|
Remission Induction | 1 | 2017 | 3621 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2024 | 4442 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2017 | 3070 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2013 | 589 | 0.020 |
Why?
|
Regression Analysis | 1 | 2014 | 1569 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2013 | 1638 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2006 | 9064 | 0.020 |
Why?
|
Myelodysplastic Syndromes | 1 | 2023 | 3063 | 0.020 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 306 | 0.020 |
Why?
|
Cell Line | 1 | 2018 | 5124 | 0.020 |
Why?
|
Sarcoma | 1 | 2021 | 1830 | 0.020 |
Why?
|
Nerve Block | 1 | 2012 | 180 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2016 | 3234 | 0.020 |
Why?
|
Influenza, Human | 1 | 2017 | 949 | 0.020 |
Why?
|
Delirium | 1 | 2012 | 206 | 0.020 |
Why?
|
Radiography | 1 | 2014 | 1944 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2018 | 5663 | 0.020 |
Why?
|
Health Status | 1 | 2012 | 616 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 5122 | 0.020 |
Why?
|
Motor Activity | 1 | 2012 | 694 | 0.020 |
Why?
|
Emotions | 1 | 2012 | 580 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2013 | 1005 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 1328 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2014 | 816 | 0.020 |
Why?
|
Body Mass Index | 1 | 2015 | 2298 | 0.020 |
Why?
|
Primary Health Care | 1 | 2014 | 847 | 0.020 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2014 | 723 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2371 | 0.020 |
Why?
|
Preoperative Care | 1 | 2013 | 1564 | 0.020 |
Why?
|
DNA | 1 | 2015 | 2735 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2012 | 2662 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 9002 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 2496 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2018 | 7299 | 0.020 |
Why?
|
Lod Score | 1 | 2005 | 162 | 0.020 |
Why?
|
Chromosome Segregation | 1 | 2005 | 83 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2015 | 7153 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2017 | 13880 | 0.010 |
Why?
|
Models, Genetic | 1 | 2005 | 1129 | 0.010 |
Why?
|
Computational Biology | 1 | 2005 | 1298 | 0.010 |
Why?
|
Mutation | 1 | 2018 | 15577 | 0.010 |
Why?
|